Tissue-adjusted pathway analysis of cancer (TPAC): A novel approach for quantifying tumor-specific gene set dysregulation relative to normal tissue

H. Robert Frost
DOI: https://doi.org/10.1371/journal.pcbi.1011717
2024-01-12
PLoS Computational Biology
Abstract:We describe a novel single sample gene set testing method for cancer transcriptomics data named tissue-adjusted pathway analysis of cancer (TPAC). The TPAC method leverages information about the normal tissue-specificity of human genes to compute a robust multivariate distance score that quantifies gene set dysregulation in each profiled tumor. Because the null distribution of the TPAC scores has an accurate gamma approximation, both population and sample-level inference is supported. As we demonstrate through an analysis of gene expression data for 21 solid human cancers from The Cancer Genome Atlas (TCGA) and associated normal tissue expression data from the Human Protein Atlas (HPA), TPAC gene set scores are more strongly associated with patient prognosis than the scores generated by existing single sample gene set testing methods. Cancer biology is highly tissue-specific: most cancer-driving somatic alterations occur in just a limited number of tissues and inherited mutations frequently have a tissue-specific functional impact. To leverage the associations between gene activity in normal and malignant tissue for gene set testing, we have developed a new single sample gene set testing method for tumor-derived transcriptomics data named TPAC (tissue-adjusted pathway analysis of cancer). The TPAC method uses normal tissue-specificity to quantifies gene set dysregulation in each profiled tumor. Importantly, we found that TPAC gene set scores are more strongly associated with patient prognosis than the scores generated by existing single sample gene set testing methods.
biochemical research methods,mathematical & computational biology
What problem does this paper attempt to address?